Man and woman listening to headphones.

Stay Connected

THE LATEST IN KROGER SPECIALTY PHARMACY

BIMZELX Logos

Kroger Specialty Pharmacy is Now Dispensing, Providing Enhanced Support, and Bridge Access for Eligible Patients for BIMZELX®

Posted on November 22, 2023 | Lake Mary, FL

UCB has selected Kroger Specialty Pharmacy as one of the Network Specialty Pharmacies to dispense BIMZELX® for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Read More
ALECENSA, GAVRETO, and ROZLYTREK Logos

Kroger Specialty Pharmacy is Now Dispensing ALECENSA®, GAVRETO®, and ROZLYTREK®

Posted on February 25, 2023 | Lake Mary, FL

Kroger Specialty Pharmacy is proud to announce it is now dispensing ALECENSA®, GAVRETO®, and ROZLYTREK® to expand our extensive list of specialty medications in Oncology.

Read More
CABENUVA Logo

Kroger Specialty Pharmacy is Now Dispensing CABENUVA

Posted on March 23, 2021 | Garden Grove, CA

Kroger Specialty Pharmacy is proud to announce it is now dispensing CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension) for treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL), on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

Read More
Xembify Logo

Kroger Specialty Infusion is Now Dispensing Xembify®

Posted on September 9, 2020 | Torrance, CA

Kroger Specialty Infusion is proud to announce it is now dispensing Xembify®, a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older.

Read More
Cuvitru Logo

Kroger Specialty Infusion is Now Dispensing Cuvitru

Posted on July 10, 2020 | Torrance, CA

Kroger Specialty Infusion is proud to announce it is now dispensing Cuvtiru, a subcutaneous treatment for patients with primary immunodeficiency (PI) in people 2 years and older.

Read More